| 摘要: |
| ［摘要］ 目的 探讨脱氢酶/还原酶9（DHRS9）在卵巢浆液性癌（SOC）中的表达特征及其潜在生物学功能，分析其与患者预后及其与SOC细胞增殖、侵袭、迁移、药物敏感性的关系，为SOC的诊断和个体化治疗提供理论依据。方法 通过癌症基因组图谱计划（TCGA）数据库及基因型-组织表达项目（GTEx）数据库分析DHRS9在SOC中的表达及其与临床特征、预后的关系。通过基因本体（GO）富集分析和京都基因与基因组百科全书（KEGG）富集分析预测其参与的生物学过程和信号通路；利用基因表达谱交互式分析（GEPIA）数据库分析DHRS9与免疫检查点的相关性。通过肿瘤免疫单细胞中心（TISCH）数据库分析DHRS9相关单细胞数据。基于癌症药物敏感性基因组学（GDSC）数据库分析DHRS9表达水平对SOC相关药物敏感性的预测价值。采用卵巢癌细胞系（OVCAR-3和SK-OV-3）进行DHRS9敲低实验，检测细胞增殖、侵袭及迁移能力。结果 DHRS9在SOC中高表达，并与较差预后显著相关（P<0.05）。GO和KEGG富集分析显示，DHRS9可能参与细胞增殖、迁移及免疫相关通路。DHRS9高表达组对紫杉醇、顺铂及吉西他滨的IC50值显著低于DHRS9低表达组（P<0.05）。DHRS9敲低显著抑制OVCAR-3和SK-OV-3细胞的增殖、迁移和侵袭能力。结论 DHRS9在SOC中高表达且与患者预后密切相关，可能通过调控细胞增殖、迁移及侵袭促进SOC发生发展。DHRS9有望成为预测抗肿瘤药物疗效的潜在生物学标志物，并为SOC治疗靶点的开发提供理论依据。 |
| 关键词: 脱氢酶/还原酶9 卵巢浆液性癌 细胞增殖与迁移 药物敏感性 |
| DOI：10.3969/j.issn.1674-3806.2026.08.04 |
| 分类号:R 737.31 |
| 基金项目:黑龙江省自然科学基金项目（编号：YQ2025H001） |
|
| Analysis of expression characteristics of DHRS9 in serous ovarian carcinoma and its potential biological roles |
|
Wang Nannan, Tong Xu, Sun Fusheng, Zhang Yongjian
|
|
Department of Gynaecology, the Sixth Affiliated Hospital of Harbin Medical University, Harbin 150028, China
|
| Abstract: |
| ［Abstract］ Objective To explore the expression characteristics and potential biological functions of dehydrogenase/reductase 9(DHRS9) in serous ovarian carcinoma(SOC), and to analyze its relationship with patient prognosis, SOC cell proliferation, invasion and migration as well as drug sensitivity, so as to provide a theoretical basis for the diagnosis and individualized treatment of SOC. Methods The expression of DHRS9 in SOC and its associations with clinical characteristics and patient prognosis were analyzed using data from The Cancer Genome Atlas(TCGA) database and the Genotype-Tissue Expression(GTEx) database. Gene Ontology(GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes(KEGG) enrichment analysis were performed to predict the biological processes and signaling pathways involving DHRS9. The Gene Expression Profiling Interactive Analysis(GEPIA) database was used to analyze the correlation between DHRS9 and immune checkpoints. DHRS9-related single-cell data were analyzed using the Tumor Immune Single-cell Hub(TISCH) database. The predictive value of DHRS9 expression levels for sensitivity to SOC-related drugs was analyzed based on the Genomics of Drug Sensitivity in Cancer(GDSC) database. DHRS9 knockdown experiments were performed on ovarian cancer cell lines OVCAR-3 and SK-OV-3, and the cell proliferation, invasion and migration abilities were assessed. Results DHRS9 was highly expressed in SOC and was significantly associated with poor prognosis(P<0.05). GO and KEGG enrichment analyses indicated that DHRS9 might be involved in cell proliferation and migration as well as immune-related pathways. The DHRS9 high-expression group exhibited significantly lower half-maximal inhibitory concentration(IC50) values for paclitaxel, cisplatin and gemcitabine than the DHRS9 low-expression group(P<0.05). Furthermore, DHRS9 knockdown significantly inhibited the proliferation, migration, and invasion abilities of OVCAR-3 and SK-OV-3 cells. Conclusion DHRS9 is highly expressed in SOC and is closely associated with patient prognosis. It may promote the occurrence and progression of SOC by regulating cell proliferation, migration and invasion. DHRS9 has the potential to serve as a biological marker for predicting the efficacy of anti-tumor drugs, which provides a theoretical basis for the development of therapeutic targets for SOC. |
| Key words: dehydrogenase/reductase 9(DHRS9) serous ovarian carcinoma(SOC) cell proliferation and migration drug sensitivity |
